A company study indicted that Celebrex is about as effective as naproxen in treating children, and both drugs had similar side effects.
Celebrex is the only Cox-2 inhibitor currently on the market. Merck's blockbuster Cox-2 drug, Vioxx (rofecoxib), was voluntarily taken off the market in September 2004 when clinical trials linked the drug to increased risk of cardiovascular events.
Bextra (valdecoxib), a Cox-2 drug marketed by Pfizer, was withdrawn in the first quarter of 2005 when it, too, was linked to increased risk of cardiovascular events.
The FDA cited a 24-week study of Celebrex involving 242 patients between the ages of two and 17 years that demonstrated its effectiveness in treating JRA. The most commonly reported side effects were cough, cold, upper respiratory tract infection, abdominal pain, headache, fever, nausea, diarrhea, and vomiting.
|Celebrex, was originally approved in 1998 for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis in adults.|